Download Investor Presentation
AXIM Biotechnologies (OTC: AXIM) is an international healthcare solutions company targeting ocular biomarkers. AXIM Eye is working with two highly specialized Point-of-Care (POC) lab testing solutions designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis.
Most Recent Shareholder Letter
Stay informed and receive company updates straight to your inbox
AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has received an initial order of 19,000...
AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022
Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,”...
AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has signed an exclusive global commercial...
Latest Annual Filing
Fiscal Year Ended Dec 31, 2021
Investor Contact Information
AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E., Suite 114, San Diego, CA 92121
T: +1 858 923-4422